EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieVergleichsstudieOpen access · CC BY-NC 4.0

A Randomised Open‐Label Comparison of Dexamphetamine and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder ( ADHD ): Symptom Response, Adherence and Weight Impact Over 12 Months

Alison Poulton iD, Sharon Ng, Hoang Cuc Do, Vincent Chau, Jessica Simons, Isabella Nilsson, Yilin Zhang, Stephanie Ng, Rosa Dyson, Habib Bhurawala iD

Journal of Paediatrics and Child Health · 2026

DOI: 10.1111/jpc.70487 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Paediatrics and Child Health, 2026. Written by Alison Poulton and 9 co-authors. Institution: Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Kingswood, New South Wales, Australia. Major MEDLINE topics: Methylphenidate, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Dextroamphetamine. 26 references. The full text is freely available (open access, CC BY-NC 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aim

Stimulant medications dexamphetamine and methylphenidate are well‐established for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), but few studies directly compare their efficacy. We aimed to compare the therapeutic and adverse effects of immediate‐release formulations of dexamphetamine and methylphenidate during the initial treatment of children with ADHD.

Methods

This open‐label study was conducted in public and private specialist paediatric clinics in New South Wales, Australia, between 2016 and 2020. One hundred stimulant‐naïve children and adolescents with DSM‐5‐confirmed ADHD were randomised 1:1 to dexamphetamine or methylphenidate. ADHD diagnosis was based on detailed clinical assessment supported by parent and teacher DSM‐5‐based ratings. Dose titration followed a standardised 4‐week weight‐based protocol monitored with weekly school‐based IOWA Conners ratings, after which dose adjustment or switching was made as clinically indicated. Participants were followed for 12 months.

Results

Study participants (mean age 9.08 [SD 2.87] years; range 4.5–16.4 years; 73% male) showed significant ADHD symptom improvement on either medication at all time periods ( p = 0.001), with no significant between‐group difference on repeated‐measures ANOVA. At 12 months, 62 participants remained on their allocated medication, with no apparent preference between methylphenidate and dexamphetamine (34/50 [68%] vs. 28/50 [56%], p = 0.15). Both medications were associated with weight loss which was greater on dexamphetamine at 3 months (−1.44 [SD 2.42] kg vs. −0.31 [SD 0.97] kg; p = 0.005).

Conclusions

Stimulant medications dexamphetamine and methylphenidate appear comparable in short‐term symptom response and 12‐month persistence after initial randomised allocation, but dexamphetamine may be associated with greater weight loss. Trial Registration: Australian New Zealand Clinical Trials Registry number: ACTRN12616000569404

Subjects

MeSH terms (MEDLINE)

MethylphenidateAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsDextroamphetamineBody WeightMedication AdherenceHumansMaleChildFemaleAdolescentNew South WalesChild, PreschoolTreatment Outcome

Author keywords

ADHDdexamphetaminemethylphenidaterandomised studyweight loss

Substances

MethylphenidateCentral Nervous System StimulantsDextroamphetamine

Authors and institutions

  • Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Kingswood, New South Wales, Australia.
  • Department of Paediatrics, Nepean Hospital, Nepean Blue Mountains Local Health District, Kingswood, New South Wales, Australia.
  • Recess Psychology, Australia.
  • School of Medicine, University of Notre Dame Australia, Sydney, New South Wales, Australia.

ORCID profiles: Alison Poulton, Habib Bhurawala

Cite

APA

Poulton, A., Ng, S., Do, H. C., Chau, V., Simons, J., Nilsson, I., Zhang, Y., Ng, S., Dyson, R., & Bhurawala, H. (2026). A Randomised Open‐Label Comparison of Dexamphetamine and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder ( ADHD ): Symptom Response, Adherence and Weight Impact Over 12 Months. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.70487

Vancouver

Poulton A, Ng S, Do HC, Chau V, Simons J, Nilsson I, et al. A Randomised Open‐Label Comparison of Dexamphetamine and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder ( ADHD ): Symptom Response, Adherence and Weight Impact Over 12 Months. Journal of Paediatrics and Child Health. 2026. doi:10.1111/jpc.70487

BibTeX
@article{Poulton2026,
  author = {Poulton, Alison and Ng, Sharon and Do, Hoang Cuc and Chau, Vincent and Simons, Jessica and Nilsson, Isabella and Zhang, Yilin and Ng, Stephanie and Dyson, Rosa and Bhurawala, Habib},
  title = {A Randomised Open‐Label Comparison of Dexamphetamine and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder ( ADHD ): Symptom Response, Adherence and Weight Impact Over 12 Months},
  journal = {Journal of Paediatrics and Child Health},
  year = {2026},
  doi = {10.1111/jpc.70487}
}
Start for free →